Glaukos是一家眼疾公司, 尽管最近损失惨重, 仍获得“Moderate Buy”评分。 Glaukos, an eye disorder company, receives a "Moderate Buy" rating despite recent losses.

Glaukos Co.(GKOS)是一家以青光眼和眼疾为主的医疗仪器供应商,其分析师的评分是正面的,共识是“Moderate Buy”,目标价格为140美元。 Glaukos Co. (GKOS), a medical instruments supplier focused on glaucoma and eye disorders, has seen positive analyst ratings, with a consensus "Moderate Buy" and a target price of $140.00. 该公司的股票主要由机构投资者拥有,最近的内幕交易包括高层主管的销售。 The company's stock is mostly owned by institutional investors, and recent insider trading includes sales by top executives. Glaukos在其最新收入报告中报告了一次损失,但比分析师的预期差高得多。 Glaukos reported a loss but beat analyst expectations in its latest earnings report.